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Cyclin-dependent kinase 5 
mediates pleiotrophin-induced 
endothelial cell migration
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Christos Polytarchou2, Spyros S. Skandalis3,4, Ulf Hellman4, Manolis Fousteris5,  
Sotirios Nikolaropoulos5, Efrosini Choleva1, Margarita Lamprou1, Angeliki Skoura6,  
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Pleiotrophin (PTN) stimulates endothelial cell migration through binding to receptor protein tyrosine 
phosphatase beta/zeta (RPTPβ/ζ) and ανβ3 integrin. Screening for proteins that interact with RPTPβ/ζ 
and potentially regulate PTN signaling, through mass spectrometry analysis, identified cyclin-
dependent kinase 5 (CDK5) activator p35 among the proteins displaying high sequence coverage. 
Interaction of p35 with the serine/threonine kinase CDK5 leads to CDK5 activation, known to be 
implicated in cell migration. Protein immunoprecipitation and proximity ligation assays verified p35-
RPTPβ/ζ interaction and revealed the molecular association of CDK5 and RPTPβ/ζ. In endothelial cells, 
PTN activates CDK5 in an RPTPβ/ζ- and phosphoinositide 3-kinase (PI3K)-dependent manner. On the 
other hand, c-Src, ανβ3 and ERK1/2 do not mediate the PTN-induced CDK5 activation. Pharmacological 
and genetic inhibition of CDK5 abolished PTN-induced endothelial cell migration, suggesting that 
CDK5 mediates PTN stimulatory effect. A new pyrrolo[2,3-α]carbazole derivative previously identified 
as a CDK1 inhibitor, was found to suppress CDK5 activity and eliminate PTN stimulatory effect on cell 
migration, warranting its further evaluation as a new CDK5 inhibitor. Collectively, our data reveal that 
CDK5 is activated by PTN, in an RPTPβ/ζ-dependent manner, regulates PTN-induced cell migration and 
is an attractive target for the inhibition of PTN pro-angiogenic properties.
Pleiotrophin (PTN) is a secreted growth factor that binds to receptor protein tyrosine phosphatase beta/zeta 
(RPTPβ/ζ) and ανβ3 integrin to stimulate human endothelial cell migration1–3. PTN regulates angiogenesis 
directly, through stimulation of endothelial cells, and indirectly through its regulatory role on the angiogenic 
effects of vascular endothelial growth factor A3. RPTPβ/ζ initiates PTN signalling through cellular Src kinase 
(c-Src) dephosphorylation and activation that consequently leads to β3 Tyr773 phosphorylation and activation of 
phosphatidylinositol 3-kinase (PI3K)2,4. Moreover, other signalling molecules, such as focal adhesion and ERK1/2 
kinases1, nitric oxide5 and xanthine oxidase6, have been shown to be activated down-stream of RPTPβ/ζ and 
required for PTN-induced endothelial cell migration. However, the cross-talk among all the identified signalling 
molecules involved, as well as novel unknown molecules that may mediate the RPTPβ/ζ migratory signalling 
pathways, are still to be investigated.
Cyclin-dependent kinases constitute a family of small serine-threonine kinases known for their major role 
in the progression of cell cycle. Among the members of the family, cyclin-dependent kinase 5 (CDK5) has no 
effect on cell cycle regulation and was initially reported as a neuronal kinase, expressed solely in the nervous 
system7. CDK5 is activated through binding to specific protein partners, p35, p39 and cyclin I, and its activity is 
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determined by the amount of available binding partners8,9. Nowadays, it is known to be expressed in several extra 
neuronal cell types and tissues and has several pathophysiological roles, among which regulation of angiogenesis 
and cancer growth8. CDK5 has been recently implicated in the development and progression of a plethora of can-
cer types (including hepatocellular carcinoma, head and neck squamous carcinoma, thyroid, breast and prostate 
cancer) and in important processes, such as angiogenesis9–13 and lymphangiogenesis14. At the cellular level, a 
major role of CDK5 is to control actin remodelling15, a process closely linked to cell migration and angiogenesis. 
However, it remains unclear how CDK5 is activated during angiogenesis.
In the current work, mechanistic and functional studies were performed to elucidate in depth the molecular 
players involved in PTN-induced, RPTPβ/ζ-mediated, cell migration with an emphasis on CDK5.
Results
RPTPβ/ζ directly interacts with CDK5 and its activator p35. To explore RPTPβ/ζ binding partners 
that potentially contribute to PTN-induced signaling, human umbilical vein endothelial cell (HUVEC) lysates 
were immunoprecipitated with an anti-RPTPβ/ζ antibody and the co-immunoprecipitated proteins were iden-
tified through MALDI-TOF MS analysis. Among the proteins co-immunoprecipitated with RPTPβ/ζ, a protein 
band of about 70 kDa was found to contain peptides identical to p35 (6 matched peptides; minimum sequence 
coverage 25%, accession No: NP_003876, Table 1). This interaction was verified by Western blot analysis (Fig. 1a), 
whereas in situ proximity ligation (PLA) assays (Fig. 1b) demonstrated formation of direct RPTPβ/ζ-p35 com-
plexes. Interestingly, from both the mass spectrometry and the Western blot assays, it was found that RPTPβ/ζ 
co-immunoprecipitates with a protein identified as p35 and recognized by a p35-specific antibody, respectively, 
which appears as a ~70 kDa p35 dimer (Fig. 1a). CDK5 was also found to co-immunoprecipitate (Fig. 1a) and 
interact (Fig. 1b) with RPTPβ/ζ, identifying the latter as a novel binding partner of CDK5/p35. CDK5-RPTPβ/ζ 
interaction does not seem to be affected, while p35-RPTPβ/ζ interaction was decreased 10 min after HUVEC 
stimulation with PTN, as shown by the in situ PLA assays (Fig. 1b).
CDK5 is required for PTN-induced cell migration. To investigate whether CDK5 has a role in 
PTN-induced endothelial cell migration, the effect of roscovitine (a CDK 1, 2 and 5 inhibitor) and NU2058 (a 
CDK 1 and 2 inhibitor) was tested. As shown in Fig. 2a, PTN-induced HUVEC migration was abolished in the 
presence of roscovitine but not NU2058, suggesting a CDK5 specific effect. The role of CDK5 in PTN-induced 
migration was verified through CDK5 suppression by means of siRNA (Fig. 2b). CDK5 knockdown results in sig-
nificant inhibition of PTN-induced HUVEC migration (Fig. 2c). Similarly, pharmacological CDK5 inhibition by 
roscovitine or genetic CDK5 down-regulation, by means of siRNA, abolished PTN-induced migration of human 
glioma U87MG cells (Supplementary Fig. S1).
PTN enhances CDK5 activity. Given that CDK5 interacts with RPTPβ/ζ and is involved in PTN-induced 
cell migration, we further investigated whether PTN affects CDK5 activity. To this end, HUVEC total cell lysates 
were immunoprecipitated with an anti-CDK5 antibody and in vitro Histone H1 phosphorylation assays were 
employed. Maximum CDK5 activity was observed within 5 min, following PTN stimulation, and was sustained 
for up to 30 min. Total CDK5 was used as the loading control (Fig. 3a). Considering that the CDK5/p35 interac-
tion leads to CDK5 activation16, we additionally tested the effect of PTN on CDK5/p35 interaction, as a means 
of CDK5 activation. Cells treated with PTN for 10 min were lysed, immunoprecipitated with a p35 antibody 
and analyzed by Western blot for CDK5. As shown in Fig. 3b, PTN induced CDK5/p35 interaction, in line 
with increased CDK5 activity. Increased CDK5/p35 interaction was verified by PLA assays (Fig. 3c), as well as 
non-radioactive CDK5 activity assay (described in Materials and Methods) (Fig. 3d).
RPTPβ/ζ and PI3K are necessary for the PTN-induced CDK5 activation. Since CDK5 interacts with 
RPTPβ/ζ and the latter is required for PTN-induced migratory signaling1,3, we tested whether RPTPβ/ζ is involved 
in PTN-induced CDK5 activation. To this end, RPTPβ/ζ was down-regulated by means of siRNA, as previously 
described1 and CDK5 activity or its interaction with p35 were assessed (with or without PTN stimulation). As shown 
in Fig. 4a and b, RPTPβ/ζ is required for PTN-induced CDK5 activation and interaction with p35.
PTN-induced cell migration is also mediated through ανβ3 integrin and specifically the 177-184 cysteine 
loop of the β3 extracellular domain2. To investigate whether PTN induces CDK5 activation through ανβ3, we 
used a synthetic peptide 177CYDMKTTC184 (B3 peptide) that corresponds to the cysteine loop mentioned 
above. This exogenously added peptide acts as a decoy for PTN thus inhibiting its interaction with αvβ32. 
Measured 
Mass (M)
Computed 
Mass Error (Da) Residues Start Residues To Missed Cut Peptide Sequence
1193.617 1193.614 0.003 261 271 0 CLSVINLMSSK
1209.611 1209.609 0.002 261 271 0 CLSVINLMSSK
1218.613 1218.635 −0.022 128 140 0 APHPAVSSAGTPK
1309.671 1309.669 0.002 1 12 0 MGTVLSLSPSYR
2282.130 2282.103 0.027 272 290 0 MLQINADPHYFTQVFSDLK
2307.129 2307.148 −0.020 13 34 1 KATLFEDGAATVGHYTAVQNSK
Table 1. Identification of cyclin-dependent kinase 5 activator 1, p35 (alt name: cyclin-dependent kinase 5 
regulatory subunit 1) by peptide mass fingerprint analysis (IP: anti-RPTPβ/ζ). This table shows the 6 tryptic 
peptides identified, expanding throughout the 25% of the human p35 sequence.
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Peptide B3 had no effect on PTN-induced CDK5-p35 interaction (Fig. 4c), suggesting that PTN binding to 
αvβ3 integrin is not involved in PTN-induced CDK5 activation. In the same line, PTN increases CDK5 activity 
and interaction with p35, in an RPTPβ/ζ-mediated manner, in rat glioma C6 cells that do not express ανβ32,4. 
Interestingly, in these cells, p35 and CDK5 co-immunoprecipitate with RPTPβ/ζ (Supplementary Fig. S2). 
Roscovitine did not inhibit PTN-induced β3Tyr773 phosphorylation either (Fig. 4d), suggesting that CDK5 is 
not upstream of ανβ3.
To further characterize the PTN-induced signaling pathway that activates CDK5, downstream of RPTPβ/ζ, 
we used pharmacological inhibitors of c-Src, PI3K and ERK1/2 kinases, known to act downstream of RPTPβ/ζ 
and to affect PTN-induced endothelial cell migration1. Inhibition of c-Src by SU6656 (a c-Src family kinase, SFK, 
Figure 1. CDK5 and its activator p35 interact with RPTPβ/ζ. (a) HUVEC lysates were immunoprecipitated 
with an antibody for RPTPβ/ζ, p35 or CDK5 and analysed by Western blot for the presence of p35 and CDK5 or 
RPTPβ/ζ. IgG was used as a negative control. Pictures are representative from four independent experiments. 
(b) Formation of CDK5-RPTPβ/ζ and p35-RPTPβ/ζ complexes as evidenced by in situ PLA in HUVEC in the 
absence or presence of exogenous PTN (100 ng/ml) for 10 min. Red color indicates the studied complexes and 
blue corresponds to nuclear Draq5 staining. Pictures are representative from two independent experiments. 
Scale bar corresponds to 10 μm. The box plots indicate the median and range of the detected signals from three 
independent experiments. n > 20 image fields, with ~4 cells per image per sample type. Each sample run at least 
in duplicate.
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inhibitor) or ERK1/2 by the MEK inhibitor U0126, did not affect PTN-induced CDK5 activation, suggesting that 
PTN activates CDK5 in an SFK- and ERK1/2-independent manner. On the contrary, the broad spectrum PI3K 
inhibitor wortmannin abolished PTN-induced CDK5 activation, suggesting that PI3K lies upstream of CDK5 
and is necessary for its activation (Fig. 5a). Inhibition of CDK5 activity by roscovitine did not affect PTN-induced 
ERK1/2 activation either (Fig. 5b), suggesting that CDK5 is not upstream of ERK1/2.
One other important signaling molecule that has been shown to be tyrosine phosphorylated by ΡΤΝ and to 
translocate into the nucleus downstream of RPTPβ/ζ, is β-catenin17. Stimulation of HUVEC with PTN for 10 min, 
did not affect β-catenin tyrosine phosphorylation or β-catenin cell membrane localization (Supplementary 
Fig. S3), suggesting that β-catenin is not involved in this pathway in endothelial cells.
Figure 2. CDK5 is involved in PTN-induced cell migration. (a) Serum-starved HUVEC were stimulated 
with PTN (100 ng/ml) in the absence or presence of roscovitine (10 μΜ) or NU2058 (10 μΜ). Migration was 
studied using the transwell assay, as described in Materials and Methods. Results are expressed as mean ± SE 
(n = 4) of the percentage change compared to untreated cells (set as default 100%). (b) Representative picture 
from Western blot analysis of total cell lysates following downregulation of CDK5 by siRNA (50 nM) in 
HUVEC. Beta-actin was used as the loading control. (c) Following downregulation of CDK5, serum-starved 
HUVEC were stimulated with PTN (100 ng/ml) and migration was measured using the transwell assay. 
Results are expressed as mean ± SE (n = 3) of the percentage change compared to untreated siNeg cells (set as 
default 100%). Untr, untransfected cells; siNeg, cells transfected with a negative control siRNA; siCDK5, cells 
transfected with siRNA for CDK5. F values of the ANOVA tests are 22.5 for (a) and 17.4 for (c).
www.nature.com/scientificreports/
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Figure 3. PTN enhances CDK5 activity. (a) Effect of PTN (100 ng/ml) on CDK5 activity as assessed by 
histone H1 phosphorylation in vitro. Total HUVEC lysates were immunoprecipitated with a CDK5 antibody 
and immunoprecipitates were incubated with histone Η1 (20 μg) and [γ-32P] ATP (20 μCi) for 30 min at 
30 °C, as described in Materials and Methods. A representative autoradiography from three independent 
experiments is presented. The bands corresponding to phosphorylated histone Η1 were quantified by image 
analysis software and normalized against total CDK5 levels in each sample. Results are expressed as mean ± SE 
(n = 3) of the percent change of histone H1 phosphorylation compared to untreated cells (set as default 100%). 
Asterisks denote statistically significant differences from the untreated cells; **P < 0.01, ***P < 0.001. F 
value of the ANOVA test is 27.2. (b) HUVEC lysates were immunoprecipitated with a p35 antibody and the 
immunoprecipitates were analysed by Western blot for the presence of CDK5 and p35. CDK5 and p35 protein 
amounts were quantified and the ratio of p35 to CDK5 was calculated in each lane. Results are expressed as 
mean ± SE (n = 8) of the percent change of CDK5/p35 ratio in PTN-stimulated vs. the untreated cells (set as 
default 100%). (c) Formation of CDK5-p35 complexes, as evidenced by in situ PLA in HUVEC in the absence 
or presence of exogenous PTN (100 ng/ml). Scale bar corresponds to 10 μm. Red color indicates the studied 
www.nature.com/scientificreports/
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Rac1 participates in the PTN migratory signaling pathway without affecting CDK5 activation. 
Based on a previous study, Cdk5 does not influence focal adhesion dynamics and microtubule organization in 
HUVEC but affects actin cytoskeleton and Rac1 activation9. It is also known that integrin-mediated cell migration 
involves Rac118. In the present work, to further elucidate how CDK5 and ανβ3 may cross-talk to mediate PTN-induced 
endothelial cell migration, we studied a possible involvement of the GTPase Rac1. To this end, we used a specific Rac1 
inhibitor, NSC23766, which can block the effect of Rac1 without interfering with the effects of RhoA and Cdc4219. 
As shown in Supplementary Fig. S4, NSC23766 abolished the stimulatory effect of PTN on HUVEC migration, sug-
gesting that Rac1 is involved in the PTN migratory signaling pathway. NSC23766 did not affect PTN-induced CDK5 
activation, suggesting that Rac1 is not upstream of CDK5 in the studied PTN signaling pathway.
Effect of pyrrolo[2,3-α]carbazole derivatives on PTN-induced CDK5 activation and endothe-
lial cell migration. We have previously described the synthesis of pyrrolo[2,3-α]carbazole derivatives and 
reported their in vitro effect on cyclin dependent kinase 1 (CDK1)20 and topoisomerase I21 activity and endothe-
lial cell proliferation21. The aim of the present work was to study the effect of the same pyrrolo[2,3-α]carbazole 
derivatives (Supplementary Fig. S5) on PTN-induced CDK5 activation and migration in HUVEC. Among all 
compounds tested, only the compound 1e exhibits a significant suppressive effect on PTN-induced CDK5 acti-
vation (Fig. 6a) and PTN-induced HUVEC migration (Fig. 6b). Similarly, compound 1e abolished PTN-induced 
migration of U87MG glioma cells (Supplementary Fig. S6).
CDK5 expression and activity are developmentally regulated in the chicken embryo chorioal-
lantoic membrane. The chicken embryo chorioallantoic membrane (CAM) is a widely used in vivo angio-
genesis assay22 and PTN has been shown to play a significant role in angiogenesis in this tissue23. In the present 
work, we studied CDK5 expression and activation during the development of CAM. As shown in Supplementary 
Fig. S7, expression and activation of CDK5 are significantly increased at day 9, compared with day 6, of embryo 
development coinciding with increased tissue angiogenesis24. Levels of both expression and activity remain prac-
tically constant till day 15 of embryo development and significantly decrease at day 18.
Discussion
In the current study we tried to characterize the endothelial cell signaling cascade involved in the pro-migratory 
effect of PTN. We mainly focused on CDK5 and its activator p35 based on the initial observation that p35 inter-
acts with RPTPβ/ζ, the receptor through which PTN initiates the endothelial migratory signaling1,2. Interestingly, 
we observed that RPTPβ/ζ mainly interacts with a ~70 kDa protein identified by MALDI-TOF and Western blot 
analyses as p35, which is possibly a p35 dimer. The literature on the existence of p35 dimers is very limited, with 
only one study showing that p35 homodimerizes and induces F-actin bundles formation25. PTN has been shown 
to differentially affect actin cytoskeleton in HUVEC26. Through specific pharmacological inhibition, we were able 
to show that Rac1 activation, a major player in actin cytoskeleton rearrangements, is involved in PTN-induced 
migratory signaling. Whether and how RPTPβ/ζ is involved in Rac1 activation and consequently to actin filament 
rearrangements, is of great interest and a mechanism to be interrogated in future studies.
Although CDK5 is mostly referred to as neuronal kinase, a possible role in angiogenesis has been further 
attributed to this molecule. The first report showed that CDK5 is expressed in proliferating and not quiescent 
bovine aortic endothelial cells; its expression is increased by basic fibroblast growth factor and mediates cell 
proliferation27. CDK5 regulates angiogenesis in vitro and in vivo in different settings9,12,28 and several roscovitine 
analogues elicit antiangiogenic effects7,29–31. This is the first study functionally linking CDK5 with PTN signal-
ing. Previous studies indicate similarities between these two molecules in normal and pathological conditions, 
especially in the nervous system, where they are both over-expressed32,33. Both PTN34,35 and CDK536,37 are sig-
nificant in brain growth and development through induction of neurite formation. PTN suppresses Long Term 
Potentiation (LTP) in hippocampus and plays a role in the regulation of learning-related behavior32,38. CDK5 
activation is implicated in LTP inhibition39, while conditional knockout CDK5 mice exhibit increased LTP40. 
CDK5 and p35/p25 may play a role in the pathogenesis of Alzheimer’s disease(AD) leading to abnormal phospho-
rylation of substrates such as tau15. ΡΤΝ is overexpressed in the brains of patients with AD41,42, but its function 
remains unknown. Both PTN and CDK5 play important role in neuromuscular junction via their participa-
tion in the accumulation of acetylcholine receptors43,44. Finally, PTN is overexpressed in microvessels after acute 
ischemic brain injury45, while CDK5 shows increased expression in endothelial cells after ischemic brain injury46. 
The latter aligns with our results showing that CDK5 mediates PΤΝ-induced endothelial cell migration.
Our previous studies have reported integrin ανβ3 as a key regulator of PTN-induced endothelial cell migra-
tion through the formation of a functional complex with RPTPβ/ζ2. In the present study, we found that ανβ3 
is not involved in PTN-induced CDK5 activation and CDK5 is not upstream of β3Tyr773 phosphorylation. 
This suggests that CDK5 activation is part of an RPTPβ/ζ-mediated signalling pathway independent of ανβ3. 
However, the data showing that both ανβ32 and CDK5 (present study) are required for PTN-induced endothe-
lial cell migration, indicate a possible cross-talk between the two pathways. One possibility would be through 
Rac1 activation downstream of CDK5. CDK5-mediated Rac1 activation in HUVEC has been previously shown 
complexes and blue corresponds to nuclear Draq5 staining. The box plots indicate the median, mean and range 
of the detected signals from three independent experiments. n > 20 image fields, with ~4 cells per image per 
sample type. Each sample run at least in duplicate. (d) CDK5 activity was measured by using the ADP-Glo 
Kinase Assay, in CDK5 immunoprecipitates from HUVEC. Results are expressed as mean ± SE (n = 14) of the 
percent change in CDK5 activity in PTN-stimulated vs the untreated cells (set as default 100%).
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Figure 4. PTN-induced CDK5 activation depends on RPTPβ/ζ but not ανβ3 integrin. (a) CDK5 activity was 
measured using the ADP-Glo Kinase Assay, in CDK5 immunoprecipitates from HUVEC following RPTPβ/ζ 
knockdown through siRNA (50 nM). Results are expressed as mean ± SE (n = 3) of the percent change in 
CDK5 activity in PTN-stimulated vs the untreated siNeg cells (set as default 100%). (b) HUVEC lysates 
following RPTPβ/ζ knockdown, through siRNA, were immunoprecipitated with a p35 antibody and the 
immunoprecipitates were analysed by Western blot for the presence of CDK5 and p35. CDK5 and p35 protein 
amounts were quantified and the ratio of p35 to CDK5 was calculated in each lane. Results are expressed as 
mean ± SE (n = 3) of the percent change of CDK5/p35 ratio in PTN-stimulated vs. the untreated siNeg cells 
(set as default 100%). siNeg, cells transfected with a negative control siRNA; siRPTPβ/ζ, cells transfected with 
siRNA for RPTPβ/ζ. (c) HUVEC cells were treated in the presence or absence of peptide B3 (1 μg/ml), known to 
block PTN-ανβ3 interaction. Whole cell lysates were immunoprecipitated for p35 and the immunoprecipitates 
were analysed by Western blot for the presence of CDK5 and p35. CDK5 and p35 protein amounts were 
www.nature.com/scientificreports/
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to be significant for endothelial cell migration9 and this agrees with our data showing that Rac1 mediates 
PTN-induced migration, without being upstream of CDK5. Rac1 has been previously shown to be activated 
in endothelial cells and mediate cell migration, downstream of PI3K but independently of Akt and ERK1/247. 
Similarly, our data show that PTN does not activate Akt in endothelial cells1 and PTN-induced CDK5 and 
ERK1/2 activation are independent of each other (this study). Interestingly, Rac1 in Drosophila regulates the 
proper cellular localization of β-integrin Myospheroid48, and in mammalian cells integrin recycling and cell 
migration involve Rac118. It is tempting therefore to speculate that PTN through CDK5 activates Rac1, which 
then controls recycling of ανβ3 and thus, endothelial cell migration. Involvement of CDK5 in ανβ3-mediated 
cell migration is further supported by the observation that in C6 glioma cells, that do not express ανβ32, phar-
macological inhibition of CDK5 by roscovitine has no effect in the inhibitory effect of PTN in the migration of 
these cells (Supplementary Fig. S2d).
To further elucidate the signaling pathway that participates in PTN-induced CDK5 activation, we used phar-
macological inhibitors of kinases that had been previously found to regulate PTN-induced endothelial cell migra-
tion down-stream of RPTPβ/ζ. The specific c-Src inhibitor SU6665 did not affect PTN-induced CDK5 activation. 
Although c-Src interacts with RPTPβ/ζ and is activated by PTN, down-stream of RPTPβ/ζ and upstream of 
ανβ31,2, it is not involved in CDK5 activation by PTN. SU6656 inhibits all SFK members, suggesting that Fyn that 
has been also shown to be activated by PTN downstream of RPTPβ/ζ49 is not involved in CDK5 activation either. 
In contrast to other cell types, such as glioma U373 cells, 3T3-L1 preadipocytes, fetal alveolar epithelial type II 
cells and cultured embryonic mouse (E14.5) neurons3, PTN stimulation of HUVEC had no effect on β-catenin 
tyrosine phosphorylation or cell membrane localization, suggesting that β-catenin is not implicated in the PTN 
pathway that leads to CDK5 activation. The reasons for the observed discrepancy related to β-catenin activation 
between HUVEC and the other types of cells are not known but could be due to the different set of receptors or 
co-receptors that participate in the effect of PTN in each cell type, or to the different ways of RPTPβ/ζ signal-
ing initiation. It has been previously shown that PTN induces RPTPβ/ζ dimerization that results in inhibition 
of tyrosine phosphatase activity and increased tyrosine phosphorylation of several substrates, such as Fyn and 
β-catenin3,17,49. On the other hand, in HUVEC, we have previously shown that upon PTN binding, RPTPβ/ζ 
dephosphorylates Tyr527 of c-Src leading to its activation, subsequent tyrosine phosphorylation of ανβ3 and 
finally increased endothelial cell migration2,3. The differences between the two possible modes of signaling down-
stream of RPTPβ/ζ are being investigated.
Similarly to SFKs, PTN-induced ERK1/2 activation is unrelated to CDK5 activation. On the other hand, PI3K 
was found to be upstream of CDK5 and affect both basal and PTN-induced CDK5 activity. These data are in 
line with previous observations that PI3K activation by brain-derived neurotrophin factor induces CDK5/p35 
interaction and CDK5 activity50, whereas PI3K inhibition leads to decreased CDK5/p35 activity51. This study may 
contradict our previous findings that PI3K lies down-stream of ανβ34. However, in all cases, we have used wort-
mannin a non-isoform specific PI3K inhibitor, which may inhibit different isoforms that function down-stream 
or upstream of ανβ3. Alternatively, the same PI3K isoform might participate in two parallel signaling pathways 
that are both downstream of RPTPβ/ζ.
Among a series of pyrrolo[2,3-α]carbazoles, we have identified one compound (1e) that inhibits CDK1 activ-
ity20, while the rest of them have a significant topoisomerase Ι inhibitory activity in vitro21. Besides topoisomerase 
I, compound 1e had no effect on the tyrosine kinase activity of several growth factor receptors20, suggesting 
selectivity for CDK1 and potentially other CDKs. In the present study, we show that 1e inhibits CDK5, which may 
be attributed to the high sequence homology of CDK5 with the mitotic CDK152 and as with previously devel-
oped inhibitors, including roscovitine, it inhibits both CDKs. The fact that compound 1e completely inhibited 
PTN-induced endothelial cell migration, further supports a central role for CDK5 in the effects of PTN on cell 
motility.
The CDK5 inhibitor roscovitine abolishes vascular endothelial growth factor-induced angiogenesis in the 
chicken embryo CAM9. In the present study, we show that CDK5 expression and activation, in chicken embryo 
CAM, is significantly increased between days 6 and 9 of embryo development, when the highest rate of endothe-
lial cell proliferation is observed in this tissue24. High levels of activity remain till maturation of the tissue blood 
vessels (day 15)24 and are decreased at later developmental stages. The levels of CDK5 activity do not correlate 
perfectly with those of ΡΤΝ or RPTPβ/ζ in the same tissue, which seem to decrease after day 12 of embryo 
development23. This indicates that CDK5 may be also regulated by other growth factors involved in CAM angio-
genesis22, such as bFGF27.
In summary, in the present study we have identified an interaction between RPTPβ/ζ, p35 and CDK5. We 
showed that PTN induces CDK5/p35 interaction and CDK5 activation downstream of RPTPβ/ζ, and that CDK5 
activation is indispensable for PTN-induced migration of endothelial cells (Fig. 7).
quantified and the ratio of p35 to CDK5 was calculated in each lane. Results are expressed as mean ± SE (n = 3) 
of the percent change of CDK5/p35 ratio in stimulated vs. the untreated cells (set as default 100%). (d) HUVEC 
were incubated with PTN (100 ng/ml) in the absence or presence of roscovitine (10 μΜ). Phosphorylation of 
β3Tyr773 was estimated in total cell lysates by Western blot as described in Materials and Methods. Phospho-
β3Tyr773 (pβ3) and total β3 (tβ3) amounts were quantified and the ratio pβ3/tβ3 was calculated in each lane. 
Results are expressed as mean ± SE (n = 3) of the percent change in phospho-β3Tyr773 relative amounts in 
PTN-stimulated vs. the untreated cells (set as default 100%). F values of the ANOVA tests are 38.7 for (a), 7.8 for 
(b), 18.2 for (c) and 11.9 for (d).
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Materials and Methods
Materials. Human recombinant PTN was purchased from PeproTech, Inc. (Rocky Hill, NJ, USA). Cell cul-
ture reagents were from Biochrom GmbH (Berlin, Germany). B3 peptide (CYDMKTTC) was from Cambridge 
Peptides (Birmingham, UK), the CDK inhibitors roscovitine and NU2058 from Santa Cruz Biotechnology, 
PP1, wortmannin and U0126 from TOCRIS (Minneapolis, MN, USA), and SU6656 and NSC23766 from 
EMD-Millipore.
Cells and cell lines. Human endothelial cells HUVEC, human glioma U87MG cells and rat glioma C6 cells 
were cultured as previously described2. Cultures were maintained at 37 °C, 5% CO2, and 100% humidity.
Mass Spectrometry. Three mg of total protein from cell lysates were immunoprecipitated with an antibody 
for RPTPβ/ζ and subjected to reduction with dithiothreitol and alkylation with iodoacetamide. After SDS-PAGE 
and silver staining of the proteins, bands were excised and treated for in-gel digestion as described53. Briefly, the 
silver was destained and trypsin (porcine, modified, sequence grade, Promega Corporation, Madison, WI, USA) 
was introduced to the dried gel pieces. After overnight tryptic digestion, peptides were bound to a C18 µZipTip 
and after washing, they were eluted with acetonitrile containing the matrix (alfa-cyano 4-hydroxycinnamic acid) 
directly onto the target plate. The mass list was generated by MALDI-TOF mass spectrometry on an Ultraflex 
TOF/TOF from Bruker Daltonics, Bremen, Germany. The search for identity was performed using the search 
engine ProFound (http://prowl.rockefeller.edu/prowl-cgi/ProFound). The spectrum was internally calibrated 
using autolytic tryptic peptides, and the error was set at +/− 0.02 Da. One missed cleavage was allowed, and 
methionine could be oxidized. The significance of the identity was judged from the search engines scoring system. 
The occurrence of the few missed cuts was either on a terminal basic residue or surrounded by acidic amino acid 
residues.
Transwell migration assays. Migration assays were performed in 24-well transwell filter plates (Costar), 
as previously described2. Briefly, harvested serum-starved cells were suspended in serum free medium supple-
mented with 0.25% bovine serum albumin (BSA). The bottom chamber was filled with 0.6 ml of serum-free 
medium supplemented with 0.25% BSA and the tested substances. The upper chamber was loaded with 0.1 ml of 
serum-free medium containing 105 cells and the chambers were incubated for 4 h at 37 °C. After completion of the 
incubation, the filters were fixed and stained with 0.33% toluidine blue solution. Migrating cells were quantified 
by counting the entire area of each filter under an Optech microscope, using a grid.
Figure 5. PTN-induced CDK5 activation depends on PI3K but not c-Src or ERK1/2. (a) CDK5 activity was 
measured in CDK5 immunoprecipitates from HUVEC previously treated with the following pharmacological 
inhibitors: SU6656 (10 μΜ), wortmannin (wortmn, 100 nM) or U0126 (20 nM). CDK5 activity was evaluated 
by using the ADP-Glo Kinase Assay. Results are expressed as mean ± SE (n = 3) of the percent change in CDK5 
activity in PTN-stimulated vs the untreated cells (set as default 100%). (b) HUVEC were incubated with PTN 
(100 ng/ml) in the absence or presence of roscovitine (10 μΜ). Phosphorylation of ERK1/2 was estimated in 
total cell lysates by Western blot as described in Materials and Methods. Phospho-ERK1/2 (pERK1/2) and 
total ERK1/2 (tERK1/2) amounts were quantified and the ratio pERK1/2/tERK1/2 was calculated in each lane. 
Results are expressed as mean ± SE (n = 3) of the percent change in phospho-ERK1/2 relative amounts in PTN-
stimulated vs. the untreated cells (set as default 100%). F values of the ANOVA tests are 15.8 for (a) and 7.8 for (b).
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RNA interference. HUVEC and U87MG cells were grown to a confluence of 50% and transfection was per-
formed in fetal bovine serum (FBS)-containing medium without antibiotics for 4 h using 50 nM of annealed RNA 
for CDK5 (#sc-29263, Santa Cruz Biotechnology, Inc) or RPTPβ/ζ1 and jetSI-ENDO (Polyplus Transfection, 
Illkirch, France) as the transfection reagent. C6 cells were grown to a confluence of 60% and transfection was 
performed in serum-free medium without antibiotics for 6 h, using 80 nM annealed RNA for RPTPβ/ζ and siRNA 
transfection reagent (#sc-29528, Santa Cruz Biotechnology, Inc). In all cases, cells were incubated for 48 h fol-
lowing transfection in FBS-containing medium and serum-starved before further experiments. Double-stranded 
negative control siRNA (#4635, Ambion, Austin, TX) was used in all experiments.
CDK5 kinase assays. CDK5 kinase assays were performed as previously described54. Briefly, cell lysates were 
harvested at defined time points following PTN stimulation, in the presence or absence of inhibitors, and were 
immunoprecipitated for CDK5. Agarose beads were washed 3 times with the lysis buffer and 2 times with a kinase 
reaction buffer containing proteinase and phosphatase inhibitors (20 mM Hepes, pH 7.4, 10 mM MgCl2, 0.5 mM 
EGTA, 10 mM DTT, 50 mM NaF, 50 mM β-glycerophosphate, 10 μg/ml aprotinin). Bead-bound kinase was then 
incubated in 20 μl of kinase buffer (20 mM Hepes, pH 7.4, 10 mM MgCl2, 0.5 mM EGTA, 10 mM DTT, 20 μM 
ATP) containing 2 μg of purified Histone H1 (#14–155, EMD-Millipore) and 20 μCi [γ-32P]ATP (BLU002A, 
PerkinElmer), at 30°C for 30 min. The reaction was terminated by adding sample loading buffer and boiling for 
Figure 6. Effect of the studied pyrrolo[2,3-α]carbazole derivatives on PTN-induced CDK5 activation and cell 
migration in vitro. (a) HUVEC were treated with the tested agents (10 μΜ) for 30 min, prior to stimulation with 
PTN (100 ng/ml) for 5 min. Whole cell lysates were immunoprecipitated for CDK5 and immunoprecipitates 
were incubated with histone Η1 (20 μg) and [γ-32P] ATP (20 μCi) for 30 min at 30 °C, as described in Materials 
and Methods. A representative autoradiography from three independent experiments is presented. The bands 
corresponding to phosphorylated histone Η1 were quantified by image analysis software and were normalized 
against total CDK5 levels in each sample. Results are expressed as mean ± SE (n = 3) of the percent change of 
histone H1 phosphorylation compared to untreated cells (set as default 100%). (b) Serum-starved HUVEC 
were stimulated by PTN (100 ng/ml) in the absence or presence of the tested agents (10 μΜ). Migration was 
measured using the transwell assay, as described in Materials and Methods. Results are expressed as mean ± SE 
(n = 3) of the percentage change compared to the corresponding untreated cells (set as default 100%). Asterisks 
denote statistically significant differences from the untreated cells; *P < 0.05, **P < 0.01, ***P < 0.001. F values 
of the ANOVA tests are 6.6 for (a) and 19.3 for (b).
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5 min. Protein samples were electrophoresed in SDS-PAGE and transferred to PVDF membranes. Substrate phos-
phorylation was analyzed by autoradiography.
Alternatively, a non-radioactive CDK5 activity assay was developed by using the ADP-Glo™ Kinase Assay kit 
(Promega Corporation) and 100 μg of total cell or tissue lysates immunoprecipitated with an antibody for CDK5.
Immunoprecipitation assay. Cells were washed twice with ice-cold PBS and lysed with PBS containing 1% 
Triton X-100, 0.1% SDS, 20 nM sodium orthovanadate, 1 μg/ml aprotinin, 1 mM PMSF and 5 mM EDTA (lysis 
buffer). Cells were scraped off the plate, kept on ice for 30 min, and centrifuged at 20,000 g for 30 min at 4 °C. The 
chorioallantoic membrane (CAM) from embryos of Leghorn fertilized eggs (Pindos, Ioannina, Greece) at differ-
ent developmental stages, was excised from the eggs, washed three times in PBS, homogenized in lysis buffer and 
centrifuged at 20,000 g for 30 min at 4 °C. Each experiment contained 4–5 eggs per data point. Equal total protein 
amounts of the supernatants from cells or CAMs were transferred to new Eppendorf tubes and incubated with 
primary antibodies for CDK5 (#sc-173, Santa Cruz Biotechnology), p35 (#sc-31102, Santa Cruz Biotechnology), 
phosphorylated tyrosine (#sc-508, Santa Cruz Biotechnology) or RPTPβ/ζ (#sc-1110, Santa Cruz Biotechnology), 
for 16 h at 4 °C under continuous agitation. IgG (#I2511, Sigma-Aldrich) was used as a negative control. Protein 
A- and protein G-agarose beads (#IP-02 and IP-04, EMD-Millipore) were added, and samples were further incu-
bated for 2 h at 4 °C. Beads and bound proteins were collected by centrifugation and washed twice with ice-cold 
PBS. The pellet was resuspended with 50 μl SDS loading buffer, heated to 95–100 °C for 5 min, and centrifuged. 
The supernatant was analysed by Western blot analysis.
Western blotting. Proteins were analysed by SDS-PAGE and transferred to PVDF membranes 
(EMD-Millipore). Blocking was performed by incubating membranes with Tris-buffered saline pH 7.4 contain-
ing Tween 20 (TBS-T), with 5% w/v nonfat dry milk for 1 h at room temperature. Membranes were further 
incubated in primary antibodies overnight at 4 °C under continuous agitation, as follows: mouse anti-RPTPβ/ζ 
(1:500 in TBS-T; #610180, BD Biosciences, San Diego, CA, USA), rabbit anti-CDK5 (1:1,000 in TBS-T; #sc-173, 
Santa Cruz Biotechnology), goat anti-p35 (1:1,000 in TBS-T; #sc-31102, Santa Cruz Biotechnology), β-catenin 
(1:1,000 in TBS-T; #9562, Cell Signaling Technology), p-integrin β3 (Tyr747) and integrin β3 (1:1,000 in TBS-T, 
#sc-20234 and sc-6627, Santa Cruz Biotechnology), phospho-p44/42 MAPK and p44/p42 MAPK (1:1,000 in 
TBS-T, #9101 and 9102, Cell Signaling Technology) and α-tubulin (1:1,000 in TBS-T, #3873, Cell Signaling 
Technology). Membranes were further washed three times with TBS-T and incubated in the corresponding 
HRP-conjugated secondary antibodies (Cell Signaling Technology or Santa Cruz Biotechnology) for 1 h at room 
temperature under continuous agitation. Membranes were washed three times with TBS-T and twice with TBS. 
Detection of immunoreactive bands was performed using the ChemiLucentTM plus Western Blot enhancing kit 
(#2650, EMD-Millipore), according to the manufacturer’s instructions. The pictures of the gels were digitized 
and the protein levels that corresponded to each immunoreactive band were quantified using the ImagePC image 
analysis software (Scion Corporation, Frederick, MD).
In situ PLA Assay. For detection of protein-protein interactions, in situ PLA was performed. The compo-
nents used (Duolink PLA Technology, Sigma-Aldrich) were as follows: anti-mouse PLA plus probe, anti-rabbit 
PLA minus probe, anti-goat PLA minus probe and Detection Reagents Orange. HUVEC were grown on cham-
ber slides (Ibidi® μ-Chamber 12 well on glass slides, Martinsried, Germany) till they reached 80% confluence. 
Following fixation and blocking, the cells were incubated with the primary antibodies: mouse anti-RPTPβ/ζ 
(1:250, #610180, BD Biosciences), rabbit anti-CDK5 (1:100 in TBS-T; #sc-173, Santa Cruz Biotechnology), mouse 
anti-CDK5 (1:100 in TBS-T; #H00001020-M01A, Abnova, Taipei, Taiwan), goat anti-p35 (1:100 in TBS-T; #sc-
31102, Santa Cruz Biotechnology). Subsequently, the cells were incubated with secondary antibodies conjugated 
with oligonucleotides, after hybridization and ligation of which, the DNA was amplified resulting in red fluo-
rescence signals. Nuclei were counterstained with Draq5; cells were mounted with Mowiol 4–88 and visualized 
Figure 7. Schematic representation of the proposed PTN pro-migratory signaling pathway that leads to CDK5 
activation in human endothelial cells. PTN induces RPTPβ/ζ stimulation that triggers an RPTPβ/ζ-p35-CDK5 
interaction. This event leads to CDK5 activation and is independent of the PTN-induced migratory signals 
through integrin ανβ3. Furthermore, RPTPβ/ζ stimulation may lead to CDK5 activation through a PI3K-
dependent manner. Finally, we show that Rac1 lies downstream of CDK5 and is necessary for PTN-induced 
endothelial cell migration.
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with Leica SP5 confocal microscope. Estimation of nuclei and cytoplasm size was performed using the Duolink 
ImageTool software. To calculate the total number of spots per cell, an algorithmic procedure was used as previ-
ously described55.
Statistical analysis. The significance of variability between the results from each group and the correspond-
ing controls was determined by unpaired t-test or ANOVA, as appropriate. Each experiment included triplicate 
measurements for each condition tested, unless otherwise indicated.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary information file.
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